Why the study?
Does simvastatin 80 mg reduce the annualised rate of whole-brain atrophy in patients aged 18-65 years with secondary progressive multiple sclerosis?
Population
140 patients aged 18-65 years with secondary progressive multiple sclerosis
Comparison
Simvastatin 80 mg vs Placebo
Design
RCT, 1:1, by a centralised web-based service with a block size of eight…
Authors
Loading...
Supports simvastatin 80 mg to slow brain atrophy in secondary progressive MS; justifies phase 3 trials for clinical outcomes.
Does simvastatin 80 mg reduce the annualised rate of whole-brain atrophy in patients aged 18-65 years with secondary progressive multiple sclerosis?
High-dose simvastatin significantly reduced the annualised rate of whole-brain atrophy compared with placebo in patients with secondary progressive multiple sclerosis, supporting its advancement to phase 3 testing.
Chataway et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: